A Case Series on Longitudinal Hypothalamic Morphology in Mild Cognitive Impairment

Article information

Ann Geriatr Med Res. 2026;30(2):285-289
Publication date (electronic) : 2026 March 31
doi : https://doi.org/10.4235/agmr.25.0122
1Melbourne School of Psychological Sciences, The University of Melbourne, Melbourne, Australia
2Faculty of Physical Culture, Palacký University Olomouc, Olomouc, Czech Republic
3Department of Obstetrics, Gynaecology & Newborn Health, Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia
4Georgia Prevention Institute, Augusta University, Augusta, GA, USA
5Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA
Corresponding Author: Jeffrey Cayaban Pagaduan, PhD Melbourne School of Psychological Sciences, The University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia E-mail: jcpagaduan@gmail.com
Received 2025 August 5; Revised 2025 December 7; Accepted 2026 March 29.

Abstract

We examined the longitudinal hypothalamic morphology in the progression of mild cognitive impairment (MCI). We used multivariable linear modelling to differentiate the structural volumetric change in the hypothalamic nuclei in nine females who developed MCI after 5 years and 61 healthy controls. We found significantly decreased left anterior-inferior (p<0.01), left anterior-superior (p<0.05), and left posterior (p<0.01) hypothalamic regions among females with MCI compared to healthy controls. There was also a significant asymmetry at the anterior-superior hypothalamus (p<0.05) in MCI females than in healthy controls. Thus, the degradation of the specific left hypothalamic subregions and leftward lateralization over time highlight the impact of early-stage MCI on the morphology of hypothalamus.

INTRODUCTION

Mild cognitive impairment (MCI) is considered the transitional stage between healthy aging and the onset of Alzheimer’s disease (AD). About one in three individuals with MCI will most likely develop AD within 5 years.1) One phenomenon affected by MCI is an alteration in the volumetric structure of the hypothalamus.2,3) The hypothalamus plays various functions to maintain homeostasis.4,5)

To date, only two studies have examined the volumetric hypothalamus in MCI.2,3) Pecher et al.2) recorded decreased hypothalamic volume in MCI. Quattrini et al.3) detected right anterior-posterior and superior tubular degradation in MCI. The aforementioned studies were conducted using a crossover design, which limited their ability to provide key insights into the progression of hypothalamic atrophy in MCI. There is also no information on hypothalamic lateralization with MCI.6)

In this case series, we investigated the longitudinal hypothalamic structural alteration occurring in early-stage MCI among females, who are more likely to experience MCI than males.7) We employed a hypothalamic segmentation technique that allowed the parcellation of 10 regions, delivering valuable information on hypothalamic morphological changes associated with the progression of MCI.8,9)

CASE REPORT

We examined sex-specific (female) brain MRI data from the Harvard Aging Brain Study, which included imaging at both the first and fifth years.10) Out of 173 females from the first year, 61 qualified as healthy controls (age 71.9±5.86 years; education 16.1±2.68 years; verbal intelligence quotient [VIQ] 123.6±7.62), while nine females (age 73.8±4.80 years; education 16.3±2.74 years; VIQ 120.3±11.8) demonstrated MCI after neuroimaging at fifth year.9) Briefly, we employed the recon-all processing stream in Freesurfer version 7.3.2 on the T1-weighted images, deriving estimated total intracranial volume (eTIV), which was normalized and used for analysis.11) Then, we conducted an automated hypothalamic segmentation to generate the following subunits:

1) Anterior-inferior (AI): suprachiasmatic nucleus, supraoptic nucleus (SON);

2) Anterior-superior (AS): preoptic area, paraventricular nucleus (PVN);

3) Posterior (P): mammillary body (including medial and lateral mammillary nuclei, lateral hypothalamus), tuberomammillary nucleus (TMN);

4) Inferior tubular (IT): infundibular or arcuate nucleus; ventromedial nucleus, SON, lateral tubular nucleus, TMN; and,

5) Superior tubular (ST): dorsomedial nucleus, PVN, lateral hypothalamus.8,9)

Fig. 1 displays an example of longitudinal hypothalamic alteration from an individual with MCI. Additionally, we assessed hypothalamic nuclei asymmetry through the lateralization index (LI), where LI = (left hypothalamus subregion volume – right hypothalamus subregion volume) / (0.5 * (left hypothalamus subregion volume + right hypothalamus subregion volume)) * 100.6) A positive LI depicts larger left than right nuclei, while a negative LI indicates greater right than left nuclei.

Fig. 1.

Hypothalamic alteration from an mild cognitive impairment participant in year 1 and year 5 (AI, anterior inferior; AS, anterior superior; IT, inferior tubular; ST, superior tubular; P, posterior).

To examine the differences in hypothalamic subunits, we used the lme4 package in R v.4.3.3 to implement multivariable linear models.12) The models included hypothalamic regions (right and left) as dependent variables, with time point (Year 1 and Year 5), age, eTIV, years in education, and VIQ as covariates.6,13) Time was modelled as a categorical factor with two levels representing the repeated measurement occasions. We included an interaction term between group and time to test whether longitudinal changes differed between groups. We utilized the Wald Test to assess the significance of the interaction term.14) Significance level was set at 0.05 level alpha.

Table 1 presents brain and hypothalamic volumes in MCI and healthy controls. We found a significant inverse relationship between age and all alterations in the left hypothalamic nuclei, as well as most changes in the right hypothalamic nuclei. A Wald test comparing models with and without group and time interaction resulted in a significantly better model fit (p<0.05) when the interaction was retained. With this method, we confirmed differential longitudinal trajectories in the left anterior-inferior (LAI, p<0.01), left anterior-superior (LAS, p<0.05), and left posterior (LP, p<0.01) between groups. Table 2 depicts the generated linear model for the left hypothalamic nuclei.

Brain and hypothalamic nuclei volumes in MCI individuals and healthy controls

Longitudinal left hypothalamic nuclei alteration in MCI individuals and healthy controls

No significant group differences were found in right anterior-inferior (RAI, p=0.08), right anterior-superior (RAS, p=0.91), right posterior (RP, p=0.35), right inferior tubular (RIT, p=0.98), and right superior tubular (RST, p=0.85). Table 3 displays the right hypothalamic nuclei alteration in MCI and healthy controls.

Longitudinal right hypothalamic nuclei alteration in MCI individuals and healthy controls

There was a significant difference in LI at AS (p<0.05). No LI differences were found in AI (p=0.37), P (p=0.08), IT (p=0.91), and ST (p=0.67).

DISCUSSION

We examined the longitudinal alteration of the hypothalamic nuclei in the progression of MCI. Results revealed volumetric reduction in the LAI, LAS, and LP hypothalamic nuclei with MCI. Further, the MCI demonstrated a greater negative lateralization index at the AS hypothalamus than the healthy group.

Indeed, we detected atrophy in the LAI, LAS, and LP hypothalamic subunits. While baseline age effects reflect cross-sectional, age-related differences in brain structure, the significant interaction of group and time demonstrates that MCI participants experienced accelerated hypothalamic atrophy beyond normal aging trajectories of the regions mentioned above, suggesting MCI-specific neurodegenerative processes. The volume loss in these areas may be due to proximity to the ventricles, increasing susceptibility to degradation.15) Another possibility is the depletion of norepinephrine within these hypothalamic subregions.7,16) Thus, structural degeneration in the LAI, LAS, and LP hypothalamic nuclei implies disruption of metabolic processes critical to cognitive functions.7,17)

In this study, we also identified LAS lateralization in MCI. The AS nuclei include the preoptic area and paraventricular nucleus. The preoptic area is essential in sleep and thermoregulation.18) On the other hand, the paraventricular nucleus is one of the autonomic control centers regulating cardiovascular, gastrointestinal, and renal functions.19) Researchers documented autonomic dysfunction20,21) and sleep disorders22,23) in MCI. Therefore, the left lateralization in the AS under MCI suggests interruption in homeostasis, potentially leading to autonomic dysfunction and poor sleep hygiene.

We acknowledge the limitations of this case series. First, the small sample size may not be sufficient for the generalizability of results to broader populations. Second, only females were included in the study, as only two males progressed to MCI, and were excluded. Such an imbalance reflects evidence suggesting that MCI is more prevalent among older females than males.7) Incorporating male populations in future studies may elucidate sex-specific alterations in MCI. Lastly, including other physiological variables may provide additional insights into the influence of hypothalamic degradation on physiological functioning.

Novelty of the Study

This is the first case series that identified longitudinal hypothalamic nuclei alterations in the development of MCI. Additionally, we also included hypothalamic lateralization to provide additional insight into MCI progression.

Conclusion

The present case series provides evidence suggesting early-stage MCI is characterized by significant hypothalamus volumetric degradation (LAI, LAS, and LP areas) and left lateralization of AS hypothalamic nuclei.

Notes

The data used in the preparation of this article were obtained from the Harvard Aging Brain Study (HABS) (P01AG036694; https://habs.mgh.harvard.edu) for which written informed consent was obtained from all participants by the original investigators. The present study involves secondary analysis of de-identified data, and no additional patient consent was required. The HABS study was launched in 2010, funded by the National Institute on Aging and is led by principal investigators Reisa A. Sperling, MD, and Keith A. Johnson, MD, at Massachusetts General Hospital/Harvard Medical School in Boston, MA, USA. The authors would like to thank the HABS for supporting this initiative.

CONFLICT OF INTEREST

The researchers claim no conflicts of interest.

FUNDING

None.

AUTHOR CONTRIBUTIONS

Conceptualization, JCP; Data curation, MBM, JCP, BB; Investigation, JCP; Methodology, JCP, BB; Project administration, JCP; Writing-original draft, JCP, BB, XW; Writing-review & editing, JCP, MBM.

References

1. Wang Y, Risacher SL, West JD, McDonald BC, Magee TR, Farlow MR, et al. Altered default mode network connectivity in older adults with cognitive complaints and amnestic mild cognitive impairment. J Alzheimers Dis 2013;35:751–60. 10.3233/jad-130080. 23481685.
2. Pecher H, Storch M, Beyer F, Witte V, Baasner CF, Schonknecht P, et al. Hypothalamic atrophy and structural covariance in amnestic mild cognitive impairment and Alzheimer’s dementia. Neuroimage Clin 2024;44:103687. 10.1016/j.nicl.2024.103687. 39406040.
3. Quattrini G, Saglia S, Agosta F, Bagattini C, Bulgari M, Canu E, et al. Atrophy of hypothalamic subunits in Alzheimer’s disease. Alzheimers Dement 2023;19e082731. 10.1002/alz.082731.
4. Ishii M, Iadecola C. Metabolic and non-cognitive manifestations of Alzheimer’s disease: the hypothalamus as both culprit and target of pathology. Cell Metab 2015;22:761–76. 10.1016/j.cmet.2015.08.016. 26365177.
5. Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci 2009;10:397–409. 10.1038/nrn2647. 19469025.
6. Low A, Mak E, Malpetti M, Chouliaras L, Nicastro N, Su L, et al. Asymmetrical atrophy of thalamic subnuclei in Alzheimer’s disease and amyloid-positive mild cognitive impairment is associated with key clinical features. Alzheimers Dement (Amst) 2019;11:690–9. 10.1016/j.dadm.2019.08.001. 31667328.
7. Liu Y, Yu X, Han P, Chen X, Wang F, Lian X, et al. Gender-specific prevalence and risk factors of mild cognitive impairment among older adults in Chongming, Shanghai, China. Front Aging Neurosci 2022;14:900523. 10.3389/fnagi.2022.900523. 36118698.
8. Billot B, Bocchetta M, Todd E, Dalca AV, Rohrer JD, Iglesias JE. Automated segmentation of the hypothalamus and associated subunits in brain MRI. Neuroimage 2020;223:117287. 10.1016/j.neuroimage.2020.117287. 32853816.
9. Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012;61:1402–18. 10.1016/j.neuroimage.2012.02.084. 22430496.
10. Dagley A, LaPoint M, Huijbers W, Hedden T, McLaren DG, Chatwal JP, et al. Harvard Aging Brain Study: dataset and accessibility. Neuroimage 2017;144:255–8. 10.1016/j.neuroimage.2015.03.069. 25843019.
11. Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004;14:11–22. 10.1093/cercor/bhg087. 14654453.
12. Bates D, Machler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw 2015;67:1–48. 10.18637/jss.v067.i01.
13. Bernstein AS, Rapcsak SZ, Hornberger M, Saranathan M. Structural changes in thalamic nuclei across prodromal and clinical Alzheimer’s disease. J Alzheimers Dis 2021;82:361–71. 10.3233/jad-201583. 34024824.
14. Wald A. Tests of statistical hypotheses concerning several parameters when the number of observations is large. Trans Am Math Soc 1943;54:426–82. 10.1090/s0002-9947-1943-0012401-3.
15. Choi EY, Tian L, Su JH, Radovan MT, Tourdias T, Tran TT, et al. Thalamic nuclei atrophy at high and heterogenous rates during cognitively unimpaired human aging. Neuroimage 2022;262:119584. 10.1016/j.neuroimage.2022.119584. 36007822.
16. Oke A, Keller R, Mefford I, Adams RN. Lateralization of norepinephrine in human thalamus. Science 1978;200:1411–3. 10.1126/science.663623. 663623.
17. Peter J, Mayer I, Kammer T, Minkova L, Lahr J, Kloppel S, et al. The relationship between cholinergic system brain structure and function in healthy adults and patients with mild cognitive impairment. Sci Rep 2021;11:16080. 10.1038/s41598-021-95573-8. 34373525.
18. Rothhaas R, Chung S. Role of the preoptic area in sleep and thermoregulation. Front Neurosci 2021;15:664781. 10.3389/fnins.2021.664781. 34276287.
19. Ferguson AV, Latchford KJ, Samson WK. The paraventricular nucleus of the hypothalamus: a potential target for integrative treatment of autonomic dysfunction. Expert Opin Ther Targets 2008;12:717–27. 10.1517/14728222.12.6.717. 18479218.
20. Collins O, Dillon S, Finucane C, Lawlor B, Kenny RA. Parasympathetic autonomic dysfunction is common in mild cognitive impairment. Neurobiol Aging 2012;33:2324–33. 10.1016/j.neurobiolaging.2011.11.017. 22188719.
21. Nicolini P, Ciulla MM, Malfatto G, Abbate C, Mari D, Rossi PD, et al. Autonomic dysfunction in mild cognitive impairment: evidence from power spectral analysis of heart rate variability in a cross-sectional case-control study. PLoS One 2014;9e96656. 10.1371/journal.pone.0096656. 24801520.
22. da Silva RA. Sleep disturbances and mild cognitive impairment: a review. Sleep Sci 2015;8:36–41. 10.1016/j.slsci.2015.02.001. 26483941.
23. Randhi B, Gutlapalli SD, Pu J, Zaidi MF, Patel M, Atluri LM, et al. Sleep disorders in mild cognitive impairment. Cureus 2023;15e36202. 10.7759/cureus.36202. 37065281.

Article information Continued

Fig. 1.

Hypothalamic alteration from an mild cognitive impairment participant in year 1 and year 5 (AI, anterior inferior; AS, anterior superior; IT, inferior tubular; ST, superior tubular; P, posterior).

Table 1.

Brain and hypothalamic nuclei volumes in MCI individuals and healthy controls

MCI Healthy
Year 1 Year 5 Year 1 Year 5
eTIV (mm3) 1,406,609.7±91,100.1 1,427,110.3±84,841.9 1,414,242.6±105,139.8 1,419,291.8±107,520.2
Left
 LAI (mm3) 16.0±3.21 12.9±3.34 17.4±2.6 16.8±2.86
 LAS (mm3) 19.4±3.34 16.3±2.99 21.9±3.6 21.0±3.37
 LP (mm3) 107.6±11.2 93.7±13.7 113.2±13.3 109.7±17.9
 LIT (mm3) 138.5±24.0 137.3±26.4 141.3±12.0 138.8±14.1
 LST (mm3) 101.3±14.2 102.3±14.4 103.3±9.13 101.6±9.92
Right
 RAI (mm3) 15.9±3.65 13.2±2.96 16.9±2.95 15.9±3.65
 RAS (mm3) 18.3±3.15 16.7±2.64 20.9±3.31 19.5±3.54
 RP (mm3) 105.6±10.7 94.9±11.5 114.7±15.8 107.7±20.4
 RIT (mm3) 123.6±18.3 123.8±21.9 128.2±10.0 127.6±14.6
 RST (mm3) 102.6±11.0 99.9±9.82 105.0±9.40 101.5±11.2

Values are presented as mean±standard deviation

MCI, mild cognitive impairment; LAI, left anterior-inferior; LAS, left anterior-superior; LP, left posterior; LIT, left inferior tubular; LST, left superior tubular; RAI, right anterior-inferior; RAS, right anterior-superior; RP, right posterior; RIT, right inferior tubular; RST, right superior tubular.

Table 2.

Longitudinal left hypothalamic nuclei alteration in MCI individuals and healthy controls

LAI LAS LP LIT LST
Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI)
eTIV (mm3) 0.00 (-0.01, 0.01) -0.00 (-0.01, 0.01) 0.02 (-0.01, 0.05) 0.04 (0.00, 0.07) 0.02 (0.00, 0.04)
Education (y) -0.03 (-0.28, 0.21) -0.03 (-0.32, 0.26) 0.24 (-1.04, 1.52) -0.17 (-1.56, 1.22) -0.63 (-1.50, 0.24)
VIQ 0.01 (-0.07, 0.09) 0.03 (-0.06, 0.12) 0.05 (-0.35, 0.46) -0.18 (-0.62, 0.26) 0.11 (-0.16., 0.39)
Age (y) -0.17 (-0.27, -0.06)** -0.29 (-0.41, -0.17)** -1.32 (-1.84, -0.80)** -0.82 (-1.39, -0.26)* -0.75 (-1.11, -0.40)**
Group -0.34 (-1.62, 2.30) 0.51 (-1.73, 2.75) -3.11 (-12.99, 6.77) -2.27 (-12.66, 8.10) -3.46 (-10.26, 3.33)
Time -2.19 (-3.81, -0.58)* -1.59 (-3.82, 0.01) -7.49 (-14.53, -0.44)* 2.26 (-3.41, 7.94) 4.54 (-0.56, 9.66)
Group×Time 2.43 (0.78, 4.08)* 2.21 (0.59, 3.83)* 10.70 (3.66, 17.74)** -0.65 (5.97, 4.70) -2.45 (-7.60, 2.71)

MCI, mild cognitive impairment; LAI, left anterior-inferior; LAS, left anterior-superior; LP, left posterior; LIT, left inferior tubular; LST, left superior tubular; eTIV, estimated total intracranial volume; VIQ, verbal intelligence quotient.

*p<0.05, **p<0.01.

Table 3.

Longitudinal right hypothalamic nuclei alteration in MCI individuals and healthy controls

RAI RAS RP RIT RST
Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI)
eTIV (mm3) 0.00 (0.00, 0.01) -0.01 (-0.01, 0.00) 0.03(-0.01, 0.06) 0.05 (0.02, 0.08)** 0.02 (0.00, 0.05)*
Education (y) 0.05 (-0.24, 0.33) 0.02 (-0.28, 0.31) -0.44 (-1.97, 1.08) -1.15 (-2.38, 0.09) -0.62 (-1.52, 0.28)
VIQ -0.02 (-0.10, 0.07) 0.00 (-0.09, 0.10) -0.02 (-0.51, 0.46) -0.06 (-0.46, 0.33) 0.19 (-0.10, 0.47)
Age (y) -0.17 (-0.29, -0.06)* -0.20 (-0.32, -0.08)** -1.34 (-1.96, -0.73)** -0.19 (-0.70, 0.31) -0.48 (-0.85, -0.12)*
Group -0.09 (-2.33, 2.15) 1.35 (-0.95, 3.64) 0.25 (-11.58, 12.08) 3.00 (-6.47, 12.46) -1.52 (-8.66, 5.61)
Time -1.94 (-3.80, -0.07)* -0.48 (-2.24, 1.28) -4.30 (-12.97, 4.39) 0.19 (-6.18, 6.57) -0.68 (-6.53, 5.21)
Group×Time 1.71 (-0.20, 3.62) 0.10 (-1.68, 1.89) 4.09 (-4.63, 12.81) -0.07 (-6.37, 6.25) -0.55 (-6.55, 5.44)

MCI, mild cognitive impairment; RAI, right anterior-inferior; RAS, right anterior-superior; RP, right posterior; RIT, right inferior tubular; RST, right superior tubular; eTIV, estimated total intracranial volume; VIQ, verbal intelligence quotient.

*p<0.05, **p<0.01.